Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
64°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Relief Therapeutics Hldg Ag
(OP:
RLFTF
)
2.550
+0.075 (+3.03%)
Streaming Delayed Price
Updated: 2:36 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Relief Therapeutics Hldg Ag
< Previous
1
2
3
4
5
6
Next >
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA
March 15, 2023
Via
ACCESSWIRE
Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars
February 28, 2023
Via
ACCESSWIRE
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa
February 14, 2023
Via
ACCESSWIRE
Relief Therapeutics Provides an Update on its Financing Strategy
February 08, 2023
Via
ACCESSWIRE
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
January 17, 2023
Via
ACCESSWIRE
Relief Therapeutics Announces Executive Leadership Team Changes
December 08, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)
November 07, 2022
Via
ACCESSWIRE
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
December 27, 2022
Via
ACCESSWIRE
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements
December 20, 2022
Via
ACCESSWIRE
Relief Therapeutics to Participate in January Investor Meetings
December 14, 2022
Via
ACCESSWIRE
Relief Announces U.S. Launch of PKU GOLIKE
October 10, 2022
Via
ACCESSWIRE
Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.
October 06, 2022
Via
ACCESSWIRE
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access
August 17, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Issuance of Shares from Authorized Capital
December 13, 2022
Via
ACCESSWIRE
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
November 21, 2022
Via
ACCESSWIRE
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
November 16, 2022
Via
ACCESSWIRE
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
November 14, 2022
Via
ACCESSWIRE
Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. Further Extend their Stay of Pending Litigation to Provide Additional Time for the Parties to Finalize their Litigation Settlement
November 08, 2022
Via
ACCESSWIRE
RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. Extend Their Stay of Pending Litigation to Provide Additional Time for The Parties to Finalize Their Settlement
October 26, 2022
Via
ACCESSWIRE
Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission
October 25, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer
October 14, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago
September 22, 2022
Via
ACCESSWIRE
Relief Reports Half-Year 2022 Results and Provides Corporate Update
September 15, 2022
Via
ACCESSWIRE
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
September 12, 2022
Via
ACCESSWIRE
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
Via
ACCESSWIRE
Relief Therapeutics Files Registration Statement on form F-1 with the U.S. Securities and Exchange Commission
August 24, 2022
Via
ACCESSWIRE
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation
August 22, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100(R) (Aviptadil)
August 03, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
July 21, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
July 21, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / July 21, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief ") announced today that the U.S. Securities and Exchange Commission (" SEC ")...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.